Additional health-related quality of life (Hrqol) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-dxd) vs ramucirumab (Ram) + paclitaxel (Ptx) in patients (Pts) with human epidermal growth factor receptor 2–positive (Her2+) unresectable/metastatic gastric cancer (Gc)/gastroesophageal junction adenocarcinoma (Geja)

by biblioteca on 19 d'octubre de 2026 with No hi ha comentaris

Shitara, K., Zaanan, A., Lonardi, S., De La Fouchardière, C., Coutzac, C., Van Cutsem, E., Dekervel, J., Shen, L., Franke, F. A., Janjigian, Y. Y., Tabernero, J., Spalding, C., Venerus, M., Souza, F., Ghiretti, A., Gumus, M., & Pietrantonio, F. (2026). Additional health-related quality of life (Hrqol) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-dxd) vs ramucirumab (Ram) + paclitaxel (Ptx) in patients (Pts) with human epidermal growth factor receptor 2–positive (Her2+) unresectable/metastatic gastric cancer (Gc)/gastroesophageal junction adenocarcinoma (Geja). Journal of Clinical Oncology, 44(16_suppl), 4111-4111. https://doi.org/10.1200/JCO.2026.44.16_suppl.4111 (Meeting abstract)